The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Commentary|Articles|June 10, 2026
ASCO 2026 Ushers in a New Era for Pancreatic Cancer, Expands Targeted Therapy Options Across the GI Spectrum
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Tracy Ann Politowicz
Oncology experts provide commentary on the meeting's biggest and most impactful presentations across the GI cancer continuum.
Advertisement
Advertisement
During the
Related to this article
D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.
Advertisement
Advertisement